Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.48M | 2.35M | 5.30M | 3.74M | 5.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.80M | 6.07M | 9.04M | 7.21M | 7.30M |
| Operating Income | -5.80M | -6.07M | -9.04M | -7.21M | -7.30M |
| Income Before Tax | -42.53M | -5.85M | -8.94M | -7.11M | -7.34M |
| Income Tax Expenses | -1.54M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.98M | -5.85M | -8.94M | -7.11M | -7.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.98M | -5.85M | -8.94M | -7.11M | -7.34M |
| EBIT | -5.80M | -6.07M | -9.04M | -7.21M | -7.30M |
| EBITDA | -5.80M | -6.07M | -9.04M | -7.15M | -7.25M |
| EPS Basic | -1.89 | -0.27 | -0.45 | -0.86 | -1.54 |
| Normalized Basic EPS | -0.16 | -0.17 | -0.28 | -0.54 | -0.96 |
| EPS Diluted | -1.89 | -0.27 | -0.45 | -0.86 | -1.54 |
| Normalized Diluted EPS | -0.16 | -0.17 | -0.28 | -0.54 | -0.96 |
| Average Basic Shares Outstanding | 21.69M | 21.66M | 19.91M | 8.30M | 4.77M |
| Average Diluted Shares Outstanding | 21.69M | 21.66M | 19.91M | 8.30M | 4.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |